Can we improve how we capture data in psychedelic trials?
Read our white paper to find out more
Last month we attended the 2023 CDISC Europe Interchange where MAC Principal SAS Programmer, Martyn Deverell, discussed his paper on how the rise in psychedelic studies should change how we look at the data to make it more reflective of the patient’s experience, improving quality and accuracy.
At MAC, we have in-depth knowledge and expertise in conducting psychedelic studies with highly experienced teams and bespoke facilities.
Our programmers understand the complexity involved in data capture when it comes to psychedelic research and suggest recommendations on how the clinical trials industry can make improvements on this.
Click to read our white paper
A Psychedelic Experience With CDISC-paper
.pdf
Download PDF • 595KB
Click to view our poster
A Psychedelic Experience With CDISC
.pdf
Download PDF • 2.02MB
